GenCanna Acquires CBD Capital Ltd

Cannabinoid Biosciences Acquires CannabidiolHemp

November 25, 2019

Consumer Products

Cannabinoid Biosciences, Inc., a California-based biopharmaceutical subsidiary of Kid Castle, has acquired CannabidiolHemp (CannabidiolHemp.net), a CBD quality aggregator and validator. The purchase is the first of multiple planned acquisitions intended to build a vertically integrated CBD distribution and supply-chain business across the United States and Canada.

GenCanna Acquires Taylor Mammon

March 22, 2021

Consumer Products

US-based GenCanna acquired London-based private-label CBD formulator and distributor Taylor Mammon, bringing the UK business into GenCanna’s vertically integrated supply chain. The deal accelerates Taylor Mammon’s Novel Foods compliance and expands GenCanna’s European distribution and private-label capabilities across consumable and topical CBD products.

22nd Century Group Acquires RX Pharmatech Ltd

January 24, 2023

Food & Beverage

22nd Century Group, through its GVB Biopharma business, acquired UK-based RX Pharmatech Ltd, a distributor of cannabinoid/CBD products and holder of numerous U.K. novel food applications. The deal includes $650,000 up-front in cash and stock plus a three-year equity earn-out tied to revenue milestones and aims to strengthen 22nd Century's access and distribution in the U.K. and EU consumer CBD market.

Curaleaf Holdings Acquires Northern Green Canada

March 19, 2024

Pharmaceuticals

Curaleaf Holdings, Inc. has signed a deal to acquire Northern Green Canada, an EU-GMP certified Canadian licensed cannabis producer, to secure high-quality indoor EU-GMP flower supply and bolster Curaleaf's European and Australasian expansion. The acquisition is expected to close in Q2 2024 pending regulatory approvals and will strengthen Curaleaf's supply chain for key markets including Germany, Australia/New Zealand and the U.K.

Curaleaf Holdings Acquires Minority Stake in Curaleaf International

July 2, 2025

Consumer Products

Curaleaf Holdings, Inc. completed the buyout of a single strategic institutional investor's equity stake in Curaleaf International Holdings Limited, bringing Curaleaf's ownership of its European holding company to 100%. The transaction was settled in Curaleaf subordinate voting shares and is intended to strengthen control and accelerate the company's strategic initiatives and expansion across European markets.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.